Arrowhead Pride Premier is our tri-weekly newsletter, one that provides analysis and exclusive insights directly from ...

We believe Arrowhead’s efforts to target RNAi to the lungs will open a new therapeutic area of exploration. In our view, this initiative may lead to RNAi economies of scale, allow for an ...

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s product pipeline includes Plozasiran, which has completed Phase 3 ...